Prostate Cancer Reports



Volume 3 Number 9
September 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 9, September

CONTENTS

PSA-only recurrence after treatment with curative intent
Definition of biochemical failure (BCF)
Natural history of biochemical failure
Post-radical prostatectomy biochemical recurrence
Post-radiotherapy biochemical recurrence
Castration-resistant prostate cancer (CRPC)
First-line treatment of mCRPC
Abiraterone
Docetaxel
Sipuleucel-T
Second-line treatment of mCRPC
Abiraterone
Enzalutamide
Docetaxel
Cabazitaxel



PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT

Definition of biochemical failure (BCF)

Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
J Urol. 2001 Apr;165(4):1146-51.
Article | PubMed abstract | Similar articles


Moul JW.
Prostate specific antigen only progression of prostate cancer.
J Urol. 2000 Jun;163(6):1632-42.
Article | PubMed abstract | Full-text PDF | Similar articles


Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.
Article | PubMed abstract | Similar articles


Natural story of biochemical failure

Post-radical prostatectomy biochemical recurrence

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.
Article | PubMed abstract | Full-text PDF | Similar articles


Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ.
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
Eur Urol. 2011 Jun;59(6):893-9. doi: 10.1016/j.eururo.2011.02.026. Epub 2011 Feb 22.
Article | PubMed abstract | Full-text PDF | Similar articles


Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.
Article | PubMed abstract | Similar articles


D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.
Article | PubMed abstract | Similar articles


Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
JAMA. 2005 Jul 27;294(4):433-9.
Article | PubMed abstract | Full-text PDF | Similar articles


Guillonneau BD, Fizazi K.
Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
Eur Urol. 2011 Jun;59(6):900-1. doi: 10.1016/j.eururo.2011.02.043. Epub 2011 Mar 17.
Article | PubMed abstract | Full-text PDF | Similar articles


Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC.
Natural history of progression after PSA elevation following radical prostatectomy.
JAMA. 1999 May 5;281(17):1591-7.
Article | PubMed abstract | Full-text PDF | Similar articles


Prediction of biochemical recurrence following salvage radiotherapy

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.
Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.
Article | PubMed abstract | Full-text PDF | Similar articles



Williams SB, Hu JC.
Predicting biochemical recurrence following salvage radiotherapy: applying lessons learned from primary radiotherapy.
Eur Urol. 2014 Sep;66(3):487-8. doi: 10.1016/j.eururo.2013.12.048. Epub 2014 Jan 2.
Article | PubMed abstract | Full-text PDF | Similar articles



Prostate cancer-specific survival following salvage radiotherapy vs observation

Eastham JA.
Words of wisdom. Re: Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. JAMA 2008;299:2760-9.
Eur Urol. 2009 Jan;55(1):247.
Article | PubMed abstract | Full-text PDF | Similar articles


Parker C, Sydes M.
Adjuvant radiotherapy after surgery for prostate cancer.
JAMA. 2008 Nov 12;300(18):2119; author reply 2119. doi: 10.1001/jama.2008.562.
Article | PubMed abstract | Full-text PDF | Similar articles



Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC.
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
JAMA. 2008 Jun 18;299(23):2760-9. doi: 10.1001/jama.299.23.2760.
Article | PubMed abstract | Full-text PDF | Similar articles


Post-radiotherapy biochemical recurrence

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.
Article | PubMed abstract | Similar articles


Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C; Trans-Tasman Radiation Oncology Group 96.01 Trialists.
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Lancet Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5. Epub 2008 Oct 15.
Article | PubMed abstract | Similar articles


Roach M 3rd.
Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes?
Eur Urol. 2015 Jun;67(6):1017-8. doi: 10.1016/j.eururo.2014.10.015. Epub 2014 Oct 28.
Article | PubMed abstract | Full-text PDF | Similar articles


Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ.
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Eur Urol. 2015 Jun;67(6):1009-16. doi: 10.1016/j.eururo.2014.09.028. Epub 2014 Oct 11.
Article | PubMed abstract | Full-text PDF | Similar articles

CASTRATION-RESISTANT PROSTATE CANCER

First-line treatment of mCRPC

Abiraterone

Ryan CJ, Fizazi K, Miller K, et al.
Final overall survival (OS) analysis of COU-AA-302, A randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (PTS) without prior chemotherapy.
Ann Oncol 2014 25((Suppl-4)): iv255-279.
Article | Journal abstract


Docetaxel

Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M.
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Clin Cancer Res. 2010 Jan 1;16(1):203-11. doi: 10.1158/1078-0432.CCR-09-2514. Epub 2009 Dec 15.
Article | PubMed abstract | Full-text PDF | Similar articles


Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators.
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461.
Article | PubMed abstract | Full-text PDF | Similar articles


Bompas E, Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Flechon A, Joly F, Ferrero J, and Fizazi K.
Docetaxel-based chemotherapy in elderly patients (
≥
75 years) with castration resistant prostate cancer (CRPC): A French National study of 175 patients.
Journal of Clinical Oncology
, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 5145
Article | Meeting abstract



Eisenberger M, Garrett-Mayer ES, Ou Yang Y, de Wit R, Tannock I, Armstrong AJ.
A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC).
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 25, No 18S (June 20 Supplement), 2007: 5058.
Article | Meeting abstract


Graff J, Lalani AS, Lee S, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN, Beer TM and ASCENT Investigators.
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial.
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 5074.
Article | Meeting abstract


Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM, Fizazi K.
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Eur Urol. 2009 Jun;55(6):1368-75. doi: 10.1016/j.eururo.2008.07.078. Epub 2008 Aug 8.
Article | PubMed abstract | Full-text PDF | Similar articles


Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM.
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.
Urol Oncol. 2012 Jan-Feb;30(1):33-7. doi: 10.1016/j.urolonc.2009.11.012. Epub 2010 Mar 6.
Article | PubMed abstract | Full-text PDF | Similar articles


Sipuleucel-T

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
Article | PubMed abstract | Full-text PDF | Similar articles


Second-line treatment of mCRPC

Abiraterone

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.
Abiraterone and increased survival in metastatic prostate cancer.
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
Article | PubMed abstract | Full-text PDF | Similar articles


Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators.
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365.
Article | PubMed abstract | Full-text PDF | Similar articles


Enzalutamide

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.
Article | PubMed abstract | Full-text PDF | Similar articles


Docetaxel

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM.
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Br J Cancer. 2004 Oct 18;91(8):1425-7.
Article | PubMed abstract | Full-text PDF | Similar articles


Ohlmann CH, Özgür E, Wille S, Engelmann U, Heidenreich A.
Second-line chemotherapy with Docetaxel for prostate specific antigen (PSA) relapse in men with hormonerefractory prostate cancer (HRPC) previously treated with Docetaxel-based chemotherapy.

Eur Urol Suppl 2006;5(2):93, abstract #289
.
Published online: 01 April 2006.
Article | Journal abstract


Ohlmann CH, Engelmann UH, Heidenreich A.
Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy.
Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 4682
Article | Meeting abstract


Cabazitaxel

Bahl A, Oudard S, Tombal B, Ozgüroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO; TROPIC Investigators.
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Ann Oncol. 2013 Sep;24(9):2402-8. doi: 10.1093/annonc/mdt194. Epub 2013 May 30.
Article | PubMed abstract | Full-text PDF | Similar articles


de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
Article | PubMed abstract | Similar articles